First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...
In combination with Keytruda, the antibody-drug conjugate slowed progression compared to anti-PD-1 therapy alone.
Morning Overview on MSN
A Boston-area trial just showed a single once-a-year shot of an mRNA vaccine pushed pancreatic-cancer patients into remission — built on each tumor’s own gen…
Eight people who had surgery for pancreatic cancer and then received a vaccine built from their own tumor DNA have now gone ...
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in ...
Tumor immune surveillance plays a pivotal role in preventing tumor formation, progression, and metastatic spread. However, cancer cells exploit several ...
The Lafayette Parish Sheriff's Office has taken issue with a report of an arrest by ICE agents in an online news source.
MedPage Today on MSN
PCSK9 inhibitors linked to better survival in some cancer patients on immunotherapy
Prospective clinical trials needed to validate the findings ...
Physical pressure can stop cancer cells from growing large enough to divide, revealing why squeezed tumors may stall.
Onc.AI, a digital health company developing computational biomarkers and decision-support products in oncology using Deep Learning imaging AI, today announced positive external validation results for ...
PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...
Immunotherapies such as so-called checkpoint inhibitors activate the body's own immune system to fight cancer cells and have revolutionized the treatment of many types of tumor. In breast cancer, ...
The latest update to the ESM protein language model series supports binder design and protein function mapping for therapeutic discovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results